AUS
NZ
UK
CA
USA
IND
Highlights
Indivior PLC to delist from the London Stock Exchange while maintaining its Nasdaq listing
The pharmaceutical company will continue to trade under ticker INDV on Nasdaq
Delisting marks a shift in listing strategy, with the firm’s primary focus on the US market
Indivior PLC (LON:INDV), a company engaged in the pharmaceutical sector, has announced plans to delist from the London Stock Exchange. The move will shift the company’s primary listing to the Nasdaq exchange in the United States, where it already trades under the same ticker, INDV. The development affects the indexftse ukx, where the company has been a constituent.
The company’s business focus involves developing treatments for addiction and serious mental health disorders. Indivior’s presence on the Nasdaq exchange aligns with its corporate base in the US, reflecting its operational and strategic emphasis on the North American market.
Board Decision Behind Delisting Strategy
The decision to remove its listing from the London Stock Exchange follows a review by the board of directors. Indivior’s leadership has aligned the delisting with broader corporate objectives, citing alignment with shareholder interest and simplification of its trading structure.
The company stated that its dual listing structure has added complexity without proportional benefits. With significant operations and stakeholders based in the US, the board has indicated that continuing solely with the Nasdaq listing under INDV will streamline corporate governance and regulatory compliance.
Timelines and Trading Continuity on Nasdaq
The timetable for delisting from the London Stock Exchange is structured to allow continuity for current shareholders. During the transition, trading of Indivior shares on Nasdaq will continue without interruption. The firm will maintain compliance with Nasdaq regulations, and its corporate communications will now primarily reflect the US listing framework.
As a result of the London delisting, the company will no longer be part of the indexftse ukx. This may impact index constituents and cause corresponding adjustments. However, operations, strategic objectives, and research activities remain unaffected by the stock exchange transition.
Impact on UK Shareholders and Corporate Governance
The change in listing venue will shift regulatory oversight and governance to US-based frameworks. Indivior has noted that it will continue to communicate with all shareholders to ensure a transparent transition.
Shareholders previously trading under the London listing will be able to access the Nasdaq listing via brokerage channels that facilitate cross-border trading. The company reiterated that governance principles and corporate structure remain intact, with board oversight continuing under Nasdaq requirements.
Industry Context and Strategic Direction
Indivior operates in the global pharmaceutical sector with a specific focus on treatments for opioid-use disorder and other central nervous system conditions. The company has cited strategic alignment with US stakeholders and its operational footprint as key factors in maintaining Nasdaq as its sole primary listing.
The delisting follows other sector developments where companies with dual listings have evaluated consolidation into a single exchange to streamline operations. Indivior’s strategic direction reflects a growing trend in the sector toward focused regional listings.
Future Reporting and Shareholder Engagement
Moving forward, all financial disclosures, regulatory filings, and investor-related documentation will be based on Nasdaq listing requirements. Indivior will continue to issue financial updates and corporate disclosures in alignment with US market standards.
The company maintains its commitment to research, patient outcomes, and business development. Shareholder engagement activities are expected to continue through virtual and physical channels facilitated under the Nasdaq framework.
